Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.46 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29097526 | 0.89 | ABL1 (0.46) | ABL1MCL1KMT2AEGLN1EGLN2 | |
| SCHEMBL28674760 | 0.85 | ABL1 (0.55) | ABL1EGLN1EGLN2 | |
| SCHEMBL3989058 | 0.84 | XDH (0.46) | ABL1L3MBTL1 | |
| SCHEMBL1203053 | 0.81 | KDM4E (0.57) | ABL1AKR1C3P4HTM | |
| SCHEMBL1201238 | 0.81 | P4HTM (0.67) | MCL1KMT2AMEN1P4HTMSRD5A2 | |
| SCHEMBL1676343 | 0.80 | XDH (0.45) | ABL1 | |
| SCHEMBL3992720 | 0.80 | SCN9A (0.47) | IGFBP3 | |
| SCHEMBL3992841 | 0.80 | EPHX2 (0.44) | ABL1KMT2AMEN1 | |
| SCHEMBL22493056 | 0.80 | MAPT (0.50) | ABL1KMT2AEGLN1EGLN2MEN1 | |
| SCHEMBL27821497 | 0.80 | EGFR (0.51) | KMT2AEGLN1EGLN2MEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410140-B2 | Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof | JUMPCAN (SHANGHAI) MEDICAL TECHNOLOGY CO., LTD (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | JUMPCAN (SHANGHAI) MEDICAL TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-110903242-B | Preparation method of Luo Shasi his intermediate | 四川科伦药物研究院有限公司 | 2023-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | SRM, SMS, SMOX | ABL1 871/4885MCL1 2691/4885KMT2A 830/4885 |
| US-12410140-B2 | Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof | SRM, SMS, SMOX | ABL1 871/4885MCL1 2691/4885KMT2A 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.